What is Agile Therapeutics, Inc. (AGRX) stock price today?

Agile Therapeutics, Inc. (AGRX) is currently trading at $1.51, up 3.42% today.

What is AGRX P/E ratio?

Agile Therapeutics, Inc.'s P/E ratio is -0.23. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is AGRX return on equity (ROE)?

Agile Therapeutics, Inc.'s return on equity (ROE) is 132.32%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Agile Therapeutics, Inc.'s market cap?

Agile Therapeutics, Inc. has a market capitalization of $10.43M.

NASDAQ · Drug Manufacturers - Specialty & Generic

Agile Therapeutics, Inc. (AGRX) Stock

$1.51 +3.42% NASDAQ: AGRX Healthcare

Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States.

Valuation

Metric	Value
Price	$1.51
Market Cap	$10.43M
P/E Ratio	-0.23
P/B Ratio	-0.20
P/S Ratio	0.53
EPS (TTM)	$-6.71
52-Week High	$2.63
52-Week Low	$0.20
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	132.32%
ROA	-141.05%
ROCE	188.98%
Gross Margin	54.18%
Operating Margin	-101.49%
Net Margin	-73.83%
Debt/Equity	-0.13
Current Ratio	0.46

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$0	$1.0M	$4.0M	$11.0M	$20.0M
Operating Profit	$-19.0M	$-49.0M	$-71.0M	$-41.0M	$-20.0M
Net Profit	$-18.0M	$-55.0M	$-77.0M	$-25.0M	$-14.0M
EPS	$-746.20	$-1291.56	$-63115.49	$-58.79	$-6.71
Op Margin	—	-6549.1%	-1731.4%	-380.7%	-101.5%

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$50.0M	$73.0M	$39.0M	$14.0M	$10.0M
Total Liabilities	$4.0M	$24.0M	$30.0M	$20.0M	$27.0M
Cash	$34.0M	$14.0M	$19.0M	$5.0M	$3.0M
Borrowings	$0	$17.0M	$18.0M	$2.0M	$2.0M

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-16.0M	$-47.0M	$-65.0M	$-36.0M	$-10.0M
Investing Cash Flow	$0	$-41.0M	$79.0M	$0	$0
Financing Cash Flow	$42.0M	$0	$0	$0	$15.0M
Net Cash Flow	$27.0M	$-20.0M	$5.0M	$-14.0M	$-3.0M
Free Cash Flow	$-16.0M	$-48.0M	$-65.0M	$-36.0M	$-10.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.79
FCF Yield	-91.86%
Quick Ratio	0.33
Interest Coverage	-14.01
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAPLApple Inc.	$313.33	+0.29%	37.72	$4.60T	0.34%
MSFTMicrosoft Corporation	$499.99	+0.03%	22.95	$3.71T	0.94%
GOOGLAlphabet Inc.	$354.30	-0.96%	27.68	$4.29T	0.23%
AMZNAmazon.com, Inc.	$274.48	+0.82%	28.76	$2.95T	0.00%
METAMeta Platforms, Inc.	$592.10	+0.37%	21.47	$1.51T	0.35%

About Agile Therapeutics, Inc.

Agile Therapeutics, Inc. operates as a women's healthcare enterprise dedicated to the research, development, and market introduction of prescription contraception in the United States. Its flagship product is Twirla (also known by its development code, AG200-15), a combined hormonal contraceptive delivered through a patch applied once weekly. The company is also progressing with several pipeline innovations, including variations of Twirla and other new products: AG200-15 Extended Regimen (ER): A regimen designed to limit a woman to four withdrawal bleeding occurrences annually. AG200-15 smaller patch (SmP): This iteration aims for shorter, lighter withdrawal bleeds and potentially enhanced contraceptive efficacy. AG200-15 ER SmP: A combined regimen that allows for an extended contraceptive cycle while simultaneously providing fewer, lighter annual bleeding episodes. P-Patch: A contraceptive patch containing only progestin, specifically intended for women who cannot or choose not to use estrogen. Agile Therapeutics, Inc. was founded in 1997 and is based in Princeton, New Jersey.

Agile Therapeutics, Inc. is headquartered in US.

Agile Therapeutics, Inc. (AGRX) stock trades at $1.51 with a market capitalization of $10.43M. The stock is valued at a price-to-earnings (P/E) ratio of -0.23, price-to-book of -0.20, price-to-sales of 0.53. Over the past 52 weeks the stock has ranged between $0.20 and $2.63, and currently trades 42.6% below its 52-week high.

On profitability, Agile Therapeutics, Inc. generates a return on equity (ROE) of 132.32% — well above the market average, a sign of a high-quality business, return on capital employed of 188.98%, an operating margin of -101.49%, a net profit margin of -73.83%.

Official website: www.agiletherapeutics.com